Nutrition Research
Volume 29, Issue 2 , Pages 114-122 , February 2009

Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma

  • Jacob P. Kunes

      Affiliations

    • College of Health Sciences, Midwestern University, Downers Grove, IL 60515, USA
    • Present address: Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA.
    • ,
  • Katie S. Cordero-Koning

      Affiliations

    • Department Biochemistry, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
    • Present address: Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA.
    • ,
  • Lionel H. Lee

      Affiliations

    • Department Biochemistry, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
    • Present address: Emergency Medicine Residency Program, Arrowhead Regional Medical Center, Colton, CA 92324, USA.
    • ,
  • Sean M. Lynch

      Affiliations

    • Department Biochemistry, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 630 515 6156; fax: +1 630 515 6319.

Received 16 November 2008 ,Revised 8 January 2009 ,Accepted 9 January 2009.

References 

  1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  2. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta. 2000;1483:217–235
  3. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77:598–625
  4. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541
  5. Young CE, Karas RH, Kuvin JT. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev. 2004;12:107–119
  6. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–480
  7. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44:6371–6382
  8. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of HDL-associated serum paraoxonase 1 (PON1) is essential for PON1-mediated inhibition of LDL oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281:7657–7665
  9. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239–1247
  10. Troughton JA, Woodside JV, Yarnell JWG, Arveiler D, Amouyel P, Ferrieres J, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis. 2008;197:556–563
  11. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA. 1989;86:6377–6381
  12. Hillstrom RJ, Yacapin-Ammons AK, Lynch SM. Vitamin C inhibits lipid oxidation in human HDL. J Nutr. 2003;133:3047–3051
  13. Calla MS, Lynch SM. Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. Arch Biochem Biophys. 2006;452:129–137
  14. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys. 2006;445:245–255
  15. Bell C, Jones PP, Seals DR. Oxidative stress does not modulate metabolic rate or skeletal muscle sympathetic activity with primary aging in adult humans. J Clin Endocrinol Metab. 2003;88:4950–4954
  16. Goldenberg H. Vitamin C: from popular food supplement to specific drug. Forum Nutr. 2003;56:42–45
  17. McGregor GP, Biesalski HK. Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2006;9:697–703
  18. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986;128:181–209
  19. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83:346–356
  20. Lowry O, Rosebrough N, Farr A, Randall R. Protein estimation with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  21. Panzenboeck U, Raitmayer S, Reicher H, Lindner H, Glatter O, Malle E, et al. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 1997;272:29711–29720
  22. Bergt C, Reicher H, Malle E, Sattler W. Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. FEBS Lett. 1999;452:295–300
  23. Carr AC, Tijerina T, Frei B. Vitamin C protects against and reverses specific hypochlorous acid– and chloramine-dependent modifications of low-density lipoprotein. Biochem J. 2000;346:491–499
  24. Marsche G, Furtmuller PG, Obinger C, Sattler W, Malle E. Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res. 2008;79:187–194
  25. Bohlen P, Stein S, Dairman W, Udenfriend S. Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys. 1973;155:213–220
  26. Kettle AJ, Winterbourn CC. Assays for the chlorination activity of myeloperoxidase. Methods Enzymol. 1994;233:502–512
  27. Esterbauer H, Dieber-Rotheneder M, Waeg M, Striegl G, Jurgens G. Biochemical, structural, and functional properties of oxidized low- density lipoprotein. Chem Res Toxicol. 1990;3:77–92
  28. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122:265–268
  29. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617–1624
  30. Khersonsky O, Tawfik DS. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem. 2006;7:49–53
  31. James RW. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med. 2006;44:1052–1059
  32. Jerlich A, Hammel M, Nigon F, Chapman MJ, Schaur RJ. Kinetics of tryptophan oxidation in plasma lipoproteins by myeloperoxidase-generated HOCl. Eur J Biochem. 2000;267:4137–4143
  33. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase 1, an antioxidant protein, and its effect on antioxidant action. Free Radic Res. 2003;37:1319–1330
  34. Sutherland WH, de Jong SA, Walker RJ. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant. 2004;19:75–82
  35. Deakin S, Moren X, James RW. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol. 2007;27:1146–1152
  36. Gugliucci A. Hypochlorous acid is a potent inactivator of human plasminogen at concentrations secreted by activated granulocytes. Clin Chem Lab Med. 2008;46:1403–1409
  37. Dabbagh AJ, Frei B. Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. J Clin Invest. 1995;96:1958–1966
  38. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783–1787
  39. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med. 1993;121:257–262
  40. Carr AC, Hawkins CL, Thomas SR, Stocker R, Frei B. Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents. Free Radic Biol Med. 2001;30:526–536
  41. Vermeer BJ, Reman FC, van Gent CM. The determination of lipids and proteins in suction blister fluid. J Invest Dermatol. 1979;73:303–305
  42. Vessby B, Gustafson S, Chapman MJ, Hellsing K, Lithell H. Lipoprotein composition of human suction-blister interstitial fluid. J Lipid Res. 1987;28:629–641
  43. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 1997;416:377–380
  44. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest. 2006;36:98–104
  45. Foote CS, Goyne TE, Lehrer RI. Assessment of chlorination by human neutrophils. Nature. 1983;301:715–716
  46. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest. 1982;70:598–607
  47. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol. 2005;25:658–670
  48. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–1276
  49. Yildiz A, Gur M, Demirbag R, Yilmaz R, Akyol S, Aslan M, et al. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin Biochem. 2008;41:779–784
  50. Yildiz A, Gur M, Yilmaz R, Demirbag R, Polat M, Selek S, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis. 2008;197:257–263
  51. Soran N, Altindag O, Cakir H, Celik H, Demirkol A, Aksoy N. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep. 2008;13:194–198
  52. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem. 2008;41:381–386
  53. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533–537
  54. Folkes LK, Candeias LP, Wardman P. Kinetics and mechanisms of hypochlorous acid reactions. Arch Biochem Biophys. 1995;323:120–126
  55. Carr AC, Frei B. Human neutrophils oxidize low-density lipoprotein by a hypochlorous acid-dependent mechanism: the role of vitamin C. Biol Chem. 2002;383:627–636
  56. Hawkins CL, Davies MJ. Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem J. 1998;332:617–625
  57. Hawkins CL, Davies MJ. Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Biochem J. 1999;340:539–548
  58. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000;20:1716–1723
  59. Carr AC. Hypochlorous acid-modified low-density lipoprotein inactivates the lysosomal protease cathepsin B: protection by ascorbic and lipoic acids. Redox Rep. 2001;6:343–349

 Presented in part as posters at Experimental Biology 2005 and Society for Free Radical Biology and Medicine 2005 meetings (SM Lynch, LH Lee. FASEB J. 2005;19:A1475-1476; SM Lynch, KS Koning. Free Rad Biol Med. 2005;39:S37) and as a thesis submitted in partial fulfillment of the requirements for the degree of Master of Biomedical Sciences (JP Kunes, Midwestern University, 2008).

PII: S0271-5317(09)00005-0

doi: 10.1016/j.nutres.2009.01.003

Nutrition Research
Volume 29, Issue 2 , Pages 114-122 , February 2009

Article Tools

* Image Usage & Resolution